Clinical Trials Browser

INDUSTRY × apatinib × Breast × Clear all

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Phase 1 Completed

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3 Unknown

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation